XBIO 015
Alternative Names: XBIO-015Latest Information Update: 08 Apr 2025
At a glance
- Originator Xenetic Biosciences
- Class Antineoplastics; Endodeoxyribonucleases; Recombinant proteins
- Mechanism of Action Extracellular trap inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 26 Mar 2025 PeriNess Ltd enters into a "Clinical Study Agreement" with Xenetic Biosciences to advance the development program for XBIO 015 in Osteosarcoma and Ewing sarcoma
- 13 Mar 2025 Pharmacodynamics data from a preclinical trial in Cancer released by Xenetic Biosciences
- 16 Dec 2024 Xenetic Biosciences and University of Virginia extends research agreement with option to acquire an exclusive license to any new intellectual property for the advancement of DNase-Based Oncology Platform for Cancer